Klavs Flemming Jensen[1] (born August 5, 1952)[2] is a chemical engineer who is currently the Warren K. Lewis Professor at the Massachusetts Institute of Technology (MIT).
[15] It eliminates the possibility of toxicity or off-target effects as it does not rely on exogenous materials or electrical fields.
[15] Jensen, along with Timothy F. Jamison, Allan Myerson and coworkers, designed a refrigerator-sized mini factory to make clinic-ready drug formulations.
[16] Chemical & Engineering News named the mini factory in their list of notable chemistry research advances from 2016.
[21] Like other cell permeablisation techniques, it enables intracellular delivery materials, such as proteins, siRNA, or carbon nanotubes.
[22] Initial applications focused on immune cells, for example delivering: The process was originally developed in 2013 by Armon Sharei and Andrea Adamo, in the lab of Langer and Jensen at Massachusetts Institute of Technology.
[25] That year, SQZBiotech won the $100,000 grand prize in the annual startup competition sponsored by Boston-based accelerator MassChallenge.
[2][4][5][28] Jensen became an Elected Fellow of the Royal Society of Chemistry in 2004 and American Association for the Advancement of Science in 2007.
[2][4][5] In May 2017, he was elected to the National Academy of Sciences in recognition of his "distinguished and continuing achievements in original research.
[2][12][35] Jensen was named in Foreign Policy magazine's 2016 list of the leading global thinkers along with Timothy F. Jamison and Allan Myerson.